Publications by authors named "H M Lazarus"
Chemo- and immune therapies administered to treat haematologic malignancies frequently cause neurologic injury. The adverse events range from mild cognitive impairment and headaches to severe conditions such as seizures, stroke and encephalitis. We performed a comprehensive literature review and report the types, mechanisms, management and prevention of neuro-toxicity resulting from these therapies in subjects who develop these toxic effects.
View Article and Find Full Text PDFBackground: The role of serotonin in pulmonary arterial hypertension has been extensively studied in recent decades, with preclinical data strongly indicating involvement in disease pathogenesis; however, clinical studies have yielded mixed results.
Methods: ELEVATE-2 was a phase 2b dose-ranging, randomised, double-blind, placebo-controlled, multicentre trial investigating rodatristat ethyl as a treatment for patients with pulmonary arterial hypertension. The study was conducted at 64 sites across 16 countries in Europe and North America.
Article Synopsis
- The SIERRA trial aimed to improve outcomes for older patients with relapsed or refractory acute myeloid leukemia (RR AML) by comparing a new treatment, I-apamistamab, against standard care before bone marrow transplant.
- The study involved 153 patients, with results showing a significantly higher durable complete remission (dCR) rate of 17.1% for the I-apamistamab group compared to 0% for the conventional care group.
- Although the overall survival rates were similar between the two groups, the I-apamistamab regimen exhibited more promise for achieving long-lasting remission with similar levels of severe side effects.